Is OGN stock a Buy, Sell, or Hold?

Based on our analysis, OGN is currently a WAIT with low confidence. 📊 MIXED SIGNALS: OGN shows conflicting indicators. Wait for confirmation before entering.

What is the fair value of OGN stock?

Our analysis estimates the fair value range for OGN to be between $13.50 and $13.67. The current price is $13.75.

What is the analyst price target for OGN?

The average Wall Street analyst price target for OGN is $11.25. This implies a potential upside of -18.2% from current levels.

OGN Stock Analysis: Buy, Sell, or Hold?

OGN - Organon & Co.

PHARMACEUTICAL PREPARATIONS

$13.75

0.01 (0.07%) ▲

5d: +0.22%

30d: +1.4%

90d: +2.46%

WAIT

LOW Confidence

Protect Your OGN Gains

Analysis Updated: Aug 21, 2026 12:00 AM ET

Earnings: Aug 04, 2026 0d

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Aug 14, 2026 at $13.70 · last confirmed Aug 21, 2026

Strength: 5.0/10

Get Alerted When OGN Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 MIXED SIGNALS: OGN shows conflicting indicators. Wait for confirmation before entering.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 25.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$19.13

Based on 14.5% avg growth

INTRINSIC VALUE TODAY

$11.88

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.7x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: OGN is currently trading at $13.75, which is considered extended relative to its 30-day fair value range of $13.50 to $13.67. From a valuation perspective, the stock is trading at a premium (Forward PE: 3.8) compared to its historical average (2.7). At these levels, the market is pricing in 11.5% annual earnings growth.

Technical Outlook: Technically, OGN is in a strong uptrend. The price is currently testing key support at $13.56. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: OGN scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $11.25. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED

Historical Trading Range $13.50 - $13.67

Company Quality Score 44/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 22.4%

Protect Your Profits

OGN is technically overbought (RSI 74). Consider hedging now to protect against a potential pullback while keeping your upside.

View Profit Protection Plan

All Signals

BEARISH: Price extended above range
BEARISH: Weak technical setup (38/100)
BULLISH: High volume confirmation
BEARISH: Trading 18.2% above Wall St target ($11.25)
BULLISH: Expecting earnings turnaround to 11.5% growth with -2.3% revenue growth
WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $13.50 - $13.67

Current vs Trading Range EXTENDED

Support & Resistance Levels

Support Level $13.56

Resistance Level $13.76

Current Trend Strong Uptrend

Technical data as of Aug 21, 2026

Fundamental Context

Forward P/E (Next Year Est.) 3.78

Wall Street Target $11.25 (-18.2%)

Revenue Growth (YoY) -2.3%

Earnings Growth (YoY) -28.3%

Profit Margin 3.4%

Valuation Premium vs History +11.5% premium

PE vs Historical 3.8 vs 2.7 STRETCHED

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +11.5% (market-implied from PE analysis)

1-Year Target $15.33 (+12%)

2-Year Target $17.09 (+24%)

3-Year Target $19.06 (+39%)

3-Yr Target (if PE normalizes) (PE: 4→3) PE COMPRESSION $13.62 (-1%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 20.1, Growth: 48.1%) $74.08 (+439%)

Base: (SPY PE: 3.8, Growth: 48.1%) $13.95 (+1%)

Bear: (PE: 2.7, Growth: 48.1%) $9.97 (-28%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (4x PE) as earnings recover.

Trailing PE: 17.60 | Current EPS (TTM): $0.78

Bull Case $30.21 (+120%)

Analyst growth 100.0%, PE expands to 19.4

Base Case $27.46 (+100%)

Market implied 100.0%, PE stable at 17.6

Bear Case $9.34 (-32%)

Severe decline -20.0%, PE contracts to 15.0

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: August 23, 2026 10:32 PM ET
Data refreshes hourly during market hours. Next update: 11:32 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is OGN showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for OGN.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
LLY Eli Lilly and Company	STRONG BUY 31 analysts	$1315	37 SELL
GILD Gilead Sciences Inc	BUY 30 analysts	$157	34 SELL
ABBV AbbVie Inc	BUY 28 analysts	$277	41 HOLD
BIIB Biogen Inc	HOLD 37 analysts	$236	42 HOLD
AMGN Amgen Inc	HOLD 32 analysts	$388	38 SELL

LLY Eli Lilly and Com…

37 SELL

GILD Gilead Sciences I…

Advanced OGN Option Strategies

Professional options setups generated by AI based on today's OGN price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for OGN

OGN Technical Chart OGN Price Prediction OGN Earnings Date OGN Investment Advisor OGN Fair Price Analyzer OGN Options Advisor OGN Options Chain OGN Options Analysis OGN Competitors

Compare OGN with Peers

OGN vs VTRS
Which one to buy?

OGN vs KD
Which one to buy?

OGN vs CTVA
Which one to buy?

OGN vs WBD
Which one to buy?

OGN vs GEHC
Which one to buy?

OGN vs GRFS
Winner: Tie

OGN vs GEHC

MIRA vs OGN

OGN vs WBD
Winner: OGN

Create New Comparison View All Competitors

Tradestie